EUVIMEDEUVIMED entdecken
Open Access

Feasibility Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease: Design and Baseline Characteristics

Stephen L Seliger, Wei Wang, Terry Watnick, Diana George, Charalett Diggs, Miranda West, Kristen Nowak, Anna Ostrow, Zhiying You, Berenice Gitomer, Michel Chonchol

American Journal of Nephrology · 08.01.2026 · 1-11

DOI: 10.1159/000549447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 08.01.2026. Verfasst von Stephen L Seliger und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland, School of Medicine, Baltimore, Maryland, USA, sseliger@som.umaryland.edu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown to slow progressive loss of kidney function in both diabetic and nondiabetic proteinuric kidney diseases. Despite the benefits of SGLT2i in patients with chronic kidney disease, the potential benefits of SGLT2i in autosomal dominant polycystic kidney disease (ADPKD) have not been assessed.

Methods

This is a randomized, placebo-controlled trial with empagliflozin (Jardiance®) with a 1-year duration and 2 participating centers, including the University of Colorado Anschutz Medical Campus and the University of Maryland Medical Center. Fifty nondiabetic ADPKD patients aged 18–55 years and estimated glomerular filtration rate of 30–90 mL/min/1.73 m2 are randomized in 1:1 ratio to receive 10 mg/day empagliflozin or a matching placebo. After 1 month, the dose is increased to 25 mg/day empagliflozin/placebo in all patients tolerating the lower dose.

Results

(Outcomes): The primary outcomes are safety and tolerability of empagliflozin, the latter determined by the percentage of patients tolerating the 25 mg dose of study drug/placebo at the end of the 12-month period. Safety is assessed by the frequency of all adverse events (AEs) and of specific AEs, including acute kidney injury, compared to placebo. Secondary outcomes include changes in total kidney volume, kidney function, aortic stiffness, copeptin level, urinary kidney injury molecule-1, and PKD-specific Health-Related Quality of Life questionnaire.

Conclusions

The outcomes of this pilot trial will provide important data regarding the safety and tolerability of empagliflozin in patients with ADPKD. Preliminary insight into the potential kidney and vascular benefits of SGLT2i will aid the design of future large-scale efficacy studies.

Schlagwörter

Stichwörter der Autor:innen

Autosomal dominant polycystic kidney diseaseEmpagliflozinSodium-glucose cotransporter 2 inhibitor

Autor:innen und Institutionen

  • University of Maryland, School of Medicine, Baltimore, Maryland, USA, sseliger@som.umaryland.edu.
  • University of Colorado, School of Medicine, Aurora, Colorado, USA.
  • University of Maryland, School of Medicine, Baltimore, Maryland, USA.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Seliger, S. L., Wang, W., Watnick, T., George, D., Diggs, C., West, M., Nowak, K., Ostrow, A., You, Z., Gitomer, B., & Chonchol, M. (2026). Feasibility Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease: Design and Baseline Characteristics. American Journal of Nephrology, 1-11. https://doi.org/10.1159/000549447

Vancouver

Seliger SL, Wang W, Watnick T, George D, Diggs C, West M, et al. Feasibility Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease: Design and Baseline Characteristics. American Journal of Nephrology. 2026:1-11. doi:10.1159/000549447

BibTeX
@article{Seliger2026,
  author = {Seliger, Stephen L and Wang, Wei and Watnick, Terry and George, Diana and Diggs, Charalett and West, Miranda and Nowak, Kristen and Ostrow, Anna and You, Zhiying and Gitomer, Berenice and Chonchol, Michel},
  title = {Feasibility Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease: Design and Baseline Characteristics},
  journal = {American Journal of Nephrology},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000549447}
}
Kostenlos starten →